# Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma

Source: https://onco.cc/trials/nct01886105/  
OnCo record `nct01886105` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Samarium-153 lexidronam in Osteosarcoma, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, recorded as terminated on the registry.

## Summary

Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma is a phase 2 interventional study registered as NCT01886105 by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, with 4 participants recorded, started 2013-08-19 and due to reach its primary completion in 2015-12-11. Interventions recorded: Sm-EDTMP, Autologous Stem Cell Infusion, External Beam Radiotherapy. Conditions recorded: Metastatic Osteosarcoma.

Linked to the drug Samarium-153 lexidronam because the registry names it among its interventions and Osteosarcoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01886105
- Phase: 2
- Setting: Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma
- Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Enrolled: 4

## Sources

- ClinicalTrials.gov NCT01886105: https://clinicaltrials.gov/study/NCT01886105

## Connected records

- cancers: [Osteosarcoma](https://onco.cc/cancers/osteosarcoma/)
- drugs: [Samarium-153 lexidronam](https://onco.cc/drugs/samarium-153-lexidronam/)

---
JSON: https://onco.cc/api/v1/entities/nct01886105.json